Status:
TERMINATED
Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse
Lead Sponsor:
Brown University
Collaborating Sponsors:
Women and Infants Hospital of Rhode Island
Rhode Island Hospital
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-80 years
Phase:
PHASE2
Brief Summary
Women with breast cancer who are not eligible for breast conserving surgery or who have node-involvement are sometimes treated with chemotherapy up front, in hopes of allowing for a woman to keep her ...
Detailed Description
For patients with locally advanced breast cancers (LABC) primary or neoadjuvant chemotherapy (NAC) has become accepted as standard treatment. Advantages of NAC include shrinking the primary tumor, oft...
Eligibility Criteria
Inclusion
- General health
- Women Age \>18.
- ECOG Performance status 0-1
- Life expectancy must be 3 months. Clinical stage
- Histologically or cytologically adenocarcinoma of breast
- Pre-operative stage II-III per AJCC 6th edition, based on baseline evaluation by clinical examination, breast imaging, and/or preoperative work-up.
- Evidence of residual invasive breast cancer or node positive disease following neoadjuvant chemotherapy.
- Prior Therapy
- Patients must have received primary (neoadjuvant) chemotherapy for local or locoregional breast cancer containing an anthracycline and a taxane.
- Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.
- Patients must have residual invasive carcinoma in the breast and/or residual carcinoma in one or more regional nodes following preoperative chemotherapy.
- Adequate hematologic and metabolic parameters within four weeks of study entry defined as:
- Absolute neutrophil count ≥1,500/mm3 Platelets ≥ 150,000/mm3
- Total bilirubin ≤ 2.0 mg/dL
- Serum creatinine ≤ 2x upper limit of normal
- Serum calcium ≤1.5x upper normal limit Concurrent treatments
- Current use of anti-coagulants is allowed as long as patients have been on a stable dose for more than 2 weeks with stable INR.
- Chronic therapy with full dose aspirin up to 325 mg/day or standard non-steroidal anti-inflammatory agents is allowed.
- Informed consent
- Provision of signed informed consent.
Exclusion
- Prior therapy
- No prior gemcitabine, continuous infusion 5-FU, or oral fluoropyrimidine (capecitabine, UFT, S-1, 5-FU/eniluracil, etc.)
- No known hypersensitivity to capecitabine or prior unanticipated severe reaction to (capecitabine, UFT, S-1, 5-FU/eniluracil, etc.) therapy or known hypersensitivity to 5-fluorouracil.
- No concurrent or prior endocrine therapy as adjuvant treatment.
- No prior breast radiation
- Current, recent (within 4 weeks of the first infusion of this study), or planned participation in another experimental drug study
- Stage IV breast cancer
- Patients must not have evidence of metastatic disease at enrollment. Women of child-bearing potential.
- Nonpregnant and nonlactating.
- Women of child-bearing potential must have a negative serum pregnancy test and must agree to an effective means of contraception during the entire study period.
- Concurrent medical conditions:
- No other active cancers, except non-melanoma skin cancers.
- No serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment.
- Patients with clinically significant medical or psychiatric problems which may interfere with treatment on study.
- Avastin-specific exclusions:
- Inadequately controlled hypertension (defined as systolic blood pressure 150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications)
- Any prior history of hypertensive crisis or hypertensive encephalopathy
- New York Heart Association (NYHA) Grade II or greater congestive heart failure
- Known CNS disease
- Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
- Symptomatic peripheral vascular disease
- Evidence of bleeding diathesis or coagulopathy
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
- Serious, non-healing wound, ulcer, or bone fracture
- Proteinuria at screening as demonstrated by urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour
- urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).
- Known hypersensitivity to any component of bevacizumab any history of stroke or transient ischemic attack at any time
- History of myocardial infarction or unstable angina within 12 months of study enrollment Inability to comply with study and/or follow-up procedures
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00462865
Start Date
November 1 2007
End Date
January 1 2014
Last Update
April 9 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of New Mexico Cancer Center
Albuquerque, New Mexico, United States, 87106
2
Lifespan Hospitals
Providence, Rhode Island, United States, 02903
3
Women & Infants' Hospital
Providence, Rhode Island, United States, 02905